Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: S01XA21Orphan Medicine

Cystadrops(mercaptamine hydrochloride)

Cystinosis

Marketing Authorisation Holder: Recordati Rare Diseases

EMA Authorisation: 18/01/2017

INN: mercaptamine

Indication

Cystadrops is indicated for the treatment of corneal cystine crystal deposits in adults and children from 6 months of age with cystinosis.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Cystadrops — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.